SPRAVATO for treatment-resistant depression: learn 5 key benefits, how esketamine works, who may qualify, and important safety considerations.
SPRAVATO is the brand name for Esketamine nasal spray, a prescription medication used in certain adults with depression.
Unlike conventional antidepressants that primarily target neurotransmitter systems such as serotonin or norepinephrine, Esketamine acts on the glutamate system, specifically as an NMDA receptor antagonist.
That difference is one reason SPRAVATO has attracted attention as an option for people whose depression hasn’t responded adequately to previous treatments.
But mechanism alone doesn’t determine whether a treatment is right for a particular patient. Clinical history, symptoms, previous treatments, other medications, medical conditions, and individual risks all matter.
SPRAVATO is indicated for treatment-resistant depression in adults. The current FDA prescribing information permits its use as monotherapy or in conjunction with an oral antidepressant.
Treatment-resistant depression generally refers to depression that has not improved adequately despite appropriate trials of antidepressant treatment. Learn more about depression and available treatment approaches from the National Institute of Mental Health.
However, simply having depression doesn’t automatically mean SPRAVATO is appropriate.
A healthcare professional needs to evaluate the person’s diagnosis, treatment history, symptoms, medical history, and potential risks before considering Esketamine.
One of the biggest challenges in treating depression is that not every medication works for every person.
Someone may try one antidepressant and experience limited improvement. Another medication might cause difficult side effects. A different treatment may help initially but not provide enough symptom relief.
For people with treatment-resistant depression, having another evidence-based treatment option can therefore be meaningful.
SPRAVATO provides an alternative approach for appropriately selected adults with TRD rather than simply repeating the same treatment strategy.
Many commonly prescribed antidepressants affect neurotransmitter systems such as serotonin or norepinephrine.
Esketamine works differently.
It is an NMDA receptor antagonist that affects the glutamate system, giving clinicians another pharmacological approach to consider when treating certain patients with treatment-resistant depression.
That doesn’t mean SPRAVATO will work when every other treatment has failed.
It means that its distinct pharmacological mechanism provides another pathway for treating depression.
This is an important update to the article.
The FDA expanded SPRAVATO’s indication in 2025 to allow monotherapy for treatment-resistant depression in adults. It can also be used alongside an oral antidepressant.
This gives clinicians greater flexibility when developing an individualized treatment plan.
Whether SPRAVATO is used alone or alongside another antidepressant depends on the patient’s circumstances and the prescribing clinician’s judgment.
SPRAVATO isn’t a medication that patients simply pick up and use at home.
Because esketamine can cause sedation, dissociation, changes in blood pressure, and other potentially serious effects, it must be administered under the direct supervision of a healthcare provider.
The FDA prescribing information requires monitoring after administration, including assessment of respiratory status and blood pressure.
Patients are generally observed for at least two hours following administration under the current safety requirements. This supervised model is an important part of SPRAVATO treatment.
Depression treatment doesn’t end simply because symptoms begin to improve.
For patients who respond to SPRAVATO, clinicians may continue treatment according to an individualized schedule designed to maintain the response or remission.
The FDA prescribing information recommends adjusting treatment frequency based on the individual’s response and tolerability, with the goal of using the least frequent dosing that maintains remission or response.
This reinforces an important point:
SPRAVATO treatment is not simply about a single dose. Ongoing assessment matters.
Like any prescription medication, SPRAVATO has potential risks and side effects.
Reported concerns include:
Because of these risks, SPRAVATO is subject to a restricted safety program known as the SPRAVATO REMS in the United States. Patients are monitored by healthcare professionals following administration.
Patients should discuss their complete medical history and current medications with their healthcare provider before beginning treatment.
A clinician may need to consider factors such as:
The decision should ultimately be individualized. And because SPRAVATO is administered under medical supervision, access also depends on finding an appropriate treatment setting.
Living with persistent depression after trying multiple treatments can be exhausting. You may begin wondering whether you’ve run out of options. You haven’t necessarily.
If SPRAVATO may be appropriate, a qualified provider can discuss the treatment, potential benefits and risks, monitoring requirements, and whether it fits your individual circumstances.
The goal isn’t simply to offer another medication. It’s to find a treatment approach that makes sense for you.
SPRAVATO is an FDA-approved treatment for treatment-resistant depression in adults. However, individual responses vary, and it isn’t effective or appropriate for everyone. A qualified clinician can determine whether it may be suitable based on your treatment history and overall health.
Yes. The FDA’s current labeling allows SPRAVATO to be used as monotherapy or alongside an oral antidepressant for adults with treatment-resistant depression.
Some patients experience improvement relatively quickly compared with the typical timeline associated with conventional antidepressants. However, response varies, and patients should not assume that one treatment session will produce immediate or complete relief.
No. SPRAVATO contains Esketamine, one component of the ketamine molecule. Although they are related, SPRAVATO is a specifically FDA-approved prescription product with its own indications, dosing, safety requirements, and monitoring procedures. FDA-approved ketamine products have different approved uses.
Patients are monitored after administration, and the FDA prescribing information requires monitoring for at least two hours following treatment. The actual visit can vary depending on the clinical setting and individual circumstances.
Yes. Potential adverse effects include sedation, dissociation, dizziness, nausea, and increased blood pressure. Because of these and other risks, SPRAVATO must be administered under healthcare-provider supervision.
When depression continues despite previous treatment, it’s understandable to feel discouraged.
But treatment-resistant depression doesn’t necessarily mean that treatment has reached a dead end.
It also comes with important safety requirements, potential side effects, and the need for careful clinical supervision.
So the question isn’t simply, “Does SPRAVATO work?”
The more useful question is:
“Could SPRAVATO be an appropriate option for my particular treatment history and needs?”
That is a conversation worth having with a qualified mental health professional.
If you’ve tried multiple depression treatments without adequate improvement, contact Pinnacle Behavioral Healthcare to discuss your symptoms, treatment history, and whether SPRAVATO or another evidence-based treatment option may be appropriate for you.
